Britain and America have secured a key commercial pact that will preserve no duties on UK medicine shipments going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost expenditure on pharmaceuticals through the NHS. This commitment secures that import taxes on these crucial goods will remain at zero for a period of the next three years.
This development follows recent statements to hike duties on branded drug imports, with potential rates discussed reaching double the cost.
"This arrangement with the United Kingdom bolsters the worldwide climate for new treatments and establishes much-needed equity to transatlantic drug exports," an announcement said.
Economic Impact
Pharmaceuticals represent one of the UK's most significant export categories to the America, which is by far the biggest destination for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period prior to the third quarter, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This figure accounted for 17.4% of total UK exports in that timeframe.
"This agreement secures employment, increases capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," a government official commented.
Specific UK Commitments
The agreement includes several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must return to the NHS to stay within budget will be capped at 15%. Last year, refunds topped twenty percent.
Recent Tensions
The pact follows a ongoing dispute between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were intensified by arguments that US customers were paying significantly more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while substantial investments have been pledged toward American operations.
One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
